DE60336334D1 - Mittel zur behandlung von blasenhyperaktivität mit einem essigsäureanilid-derivat als wirkstoff - Google Patents

Mittel zur behandlung von blasenhyperaktivität mit einem essigsäureanilid-derivat als wirkstoff

Info

Publication number
DE60336334D1
DE60336334D1 DE60336334T DE60336334T DE60336334D1 DE 60336334 D1 DE60336334 D1 DE 60336334D1 DE 60336334 T DE60336334 T DE 60336334T DE 60336334 T DE60336334 T DE 60336334T DE 60336334 D1 DE60336334 D1 DE 60336334D1
Authority
DE
Germany
Prior art keywords
bladder
derivative
hyperactivity
blood
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60336334T
Other languages
German (de)
English (en)
Inventor
Toshiyuki Takasu
Shuichi Sato
Masashi Ukai
Tatsuya Maruyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32310425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60336334(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of DE60336334D1 publication Critical patent/DE60336334D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60336334T 2002-11-07 2003-11-04 Mittel zur behandlung von blasenhyperaktivität mit einem essigsäureanilid-derivat als wirkstoff Expired - Lifetime DE60336334D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002323792 2002-11-07
PCT/JP2003/014065 WO2004041276A1 (ja) 2002-11-07 2003-11-04 酢酸アニリド誘導体を有効成分とする過活動膀胱治療剤

Publications (1)

Publication Number Publication Date
DE60336334D1 true DE60336334D1 (de) 2011-04-21

Family

ID=32310425

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60336334T Expired - Lifetime DE60336334D1 (de) 2002-11-07 2003-11-04 Mittel zur behandlung von blasenhyperaktivität mit einem essigsäureanilid-derivat als wirkstoff

Country Status (28)

Country Link
US (5) US7750029B2 (enExample)
EP (1) EP1559427B1 (enExample)
JP (1) JP3815496B2 (enExample)
KR (1) KR100967070B1 (enExample)
CN (1) CN100406011C (enExample)
AT (1) ATE500827T1 (enExample)
AU (1) AU2003284700B2 (enExample)
BE (1) BE2013C040I2 (enExample)
BR (1) BR0316080A (enExample)
CA (1) CA2503570C (enExample)
CY (2) CY1111399T1 (enExample)
DE (1) DE60336334D1 (enExample)
DK (1) DK1559427T3 (enExample)
ES (1) ES2360353T3 (enExample)
FR (1) FR13C0032I2 (enExample)
HU (1) HUS1300027I1 (enExample)
IL (1) IL168121A (enExample)
LU (1) LU92218I2 (enExample)
MX (1) MXPA05004925A (enExample)
NL (1) NL300599I2 (enExample)
NO (2) NO334948B1 (enExample)
NZ (1) NZ539577A (enExample)
PL (1) PL211687B1 (enExample)
PT (1) PT1559427E (enExample)
RU (1) RU2321401C2 (enExample)
SI (1) SI1559427T1 (enExample)
WO (1) WO2004041276A1 (enExample)
ZA (1) ZA200503510B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10351271A1 (de) * 2003-10-31 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung der Stressinkontinenz und/oder Mischinkontinenz
PT2216021E (pt) 2007-11-02 2012-11-06 Astellas Pharma Inc Composição farmacêutica para tratar uma bexiga hiperactiva
CA2709727A1 (en) * 2007-12-21 2009-07-02 Astellas Pharma Inc. Pharmaceutical composition for improving lower urinary tract symptoms
PE20091825A1 (es) * 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
TWI478712B (zh) * 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
WO2010053068A1 (ja) * 2008-11-07 2010-05-14 大日本住友製薬株式会社 新規で有用な下部尿路症状治療剤
WO2010147830A2 (en) 2009-06-15 2010-12-23 Auspex Pharmaceuticals, Inc. Aminothiazole modulators of beta-3-adrenoreceptor
TR201802207T4 (tr) * 2010-03-29 2018-03-21 Astellas Pharma Inc Kontrollü Salımlı Farmasötik Bileşim.
WO2011122523A1 (ja) * 2010-03-29 2011-10-06 アステラス製薬株式会社 放出制御医薬組成物
US9655885B2 (en) 2011-05-18 2017-05-23 Dr. Reddy's Laboratories Ltd. Amorphous mirabegron and processes for crystal forms of mirabegron
IN2013CN09704A (enExample) * 2011-05-18 2015-07-03 Reddys Lab Ltd Dr
JPWO2013147134A1 (ja) 2012-03-30 2015-12-14 アステラス製薬株式会社 ミラベグロン含有医薬組成物
CN104602693A (zh) 2012-08-31 2015-05-06 安斯泰来制药株式会社 口服给药用药物组合物
WO2014132270A2 (en) * 2013-02-27 2014-09-04 Msn Laboratories Limited Process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-{[(2r)-2-hydroxy-2-phenyl ethyl]amino}ethyl)phenyl]acetamide monohydrochloride, its intermediates and polymorph thereof
CN103193730A (zh) * 2013-04-17 2013-07-10 苏州永健生物医药有限公司 一种米拉贝隆的合成方法
CN103232368B (zh) * 2013-04-18 2015-08-12 苏州永健生物医药有限公司 一种(r)-4-硝基苯乙基-(2-羟基-2-苯乙基)-氨基甲酸叔丁酯的合成方法
CN103193658A (zh) * 2013-04-18 2013-07-10 苏州永健生物医药有限公司 一种（r）-2-对硝基苯乙胺基-1-苯乙醇及其盐的合成方法
CN103232352B (zh) * 2013-05-11 2015-12-23 苏州永健生物医药有限公司 (r)-4-(2-(2-羟基-2-苯乙胺基)乙基)苯胺基甲酸叔丁基酯
CN105579057A (zh) * 2013-07-23 2016-05-11 阿勒根公司 包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物
ITMI20131653A1 (it) * 2013-10-07 2015-04-08 Dipharma Francis Srl Forme cristalline di un agonista adrenergico
RU2550968C1 (ru) * 2013-11-29 2015-05-20 Федеральное государственное бюджетное учреждение "Научный центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Комплексный способ лечения пациенток с хроническими рецидивирующими циститами и рефрактерным гиперактивным мочевым пузырем
WO2015155664A1 (en) * 2014-04-08 2015-10-15 Suven Life Sciences Limited An improved process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-[[(2r)-2-hydroxy-2- phenylethyl]amino]-ethyl)phenyl]acetamide
WO2015162536A1 (en) * 2014-04-22 2015-10-29 Calyx Chemicals And Pharmaceuticals Ltd. Novel process for preparation of mirabegron and it's intermediate
CN104016943A (zh) * 2014-05-23 2014-09-03 苏州凯瑞医药科技有限公司 一种米拉贝隆的合成方法
CN104016877B (zh) * 2014-06-13 2017-02-15 南京海融制药有限公司 一种苯基乙酰胺类化合物及在制备米拉贝隆中的应用
CN104230840A (zh) * 2014-09-05 2014-12-24 安徽联创药物化学有限公司 米拉贝隆的合成方法
JP2017535567A (ja) 2014-11-20 2017-11-30 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ アルファ−アドレナリン受容体拮抗薬と組み合わせたデスモプレシンを含む方法及び組成物
CN104496841B (zh) * 2014-11-26 2017-01-25 南京工业大学 一种米拉贝隆中间体的合成方法
CN104744292A (zh) * 2015-03-11 2015-07-01 南京工业大学 (r)-2-((4-硝基苯乙基)氨基)-2-氧代-1-苯乙基乙酸酯或其衍生物的制备方法
JP2018090490A (ja) 2015-03-31 2018-06-14 アステラス製薬株式会社 ミラベグロン含有医薬組成物
JP6618736B2 (ja) 2015-09-01 2019-12-11 沢井製薬株式会社 ミラベグロン含有錠剤、ミラベグロン含有製剤の製造方法及びミラベグロン含有造粒物の製造方法
CN106278909B (zh) * 2016-08-12 2022-07-15 浙江华海药业股份有限公司 一种米拉贝隆中间体的后处理方法
EP3489224A1 (en) 2017-02-14 2019-05-29 Alfred E. Tiefenbacher (GmbH & Co. KG) Mirabegron prodrugs
KR102051132B1 (ko) * 2017-03-17 2019-12-02 주식회사 종근당 미라베그론 또는 이의 염을 포함하는 방출조절용 약제학적 조성물
KR101868438B1 (ko) 2017-04-13 2018-06-20 (주) 성운파마코피아 아미드 유도체의 제조방법
US11123320B2 (en) 2017-05-31 2021-09-21 Sbi Pharmaceuticals, Co., Ltd. Prophylactic or therapeutic agent for hyperaciive bladder
EP4410295A3 (en) 2017-06-06 2024-10-16 Urovant Sciences GmbH Use of vibegron to treat overactive bladder
KR102398639B1 (ko) 2017-06-20 2022-05-17 (주) 성운파마코피아 아미드 유도체의 염 및 그 제조방법
KR101937713B1 (ko) 2017-07-14 2019-01-14 주식회사 대웅제약 약제학적 제제 및 그 제조방법
WO2019013583A2 (ko) 2017-07-14 2019-01-17 주식회사 대웅제약 약제학적 제제 및 그 제조방법
NZ774649A (en) 2018-12-05 2025-07-25 Urovant Sciences Gmbh Vibegron for the treatment of overactive bladder symptoms
KR20200117091A (ko) 2019-04-02 2020-10-14 제이투에이치바이오텍 (주) 미라베그론 전구체 약물 화합물 및 이의 과민성 방광 질환의 치료 또는 개선을 위한 의약 용도
EP3722285B1 (en) 2020-04-08 2022-03-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Process for preparing mirabegron enacarbil
CN113816864B (zh) * 2020-06-18 2024-03-29 南京正大天晴制药有限公司 一种(r)-2-羟基-n-[2-(4-氨基苯基)乙基]-2-苯乙胺的制备方法
KR20220081033A (ko) 2020-12-08 2022-06-15 주식회사 한서켐 미라베그론 α형 결정의 제조방법
EP4338729A1 (en) 2022-09-19 2024-03-20 Sanovel Ilac Sanayi Ve Ticaret A.S. A tablet comprising mirabegron
EP4410279A1 (en) 2023-01-25 2024-08-07 Sanovel Ilac Sanayi Ve Ticaret A.S. A film tablet comprising mirabegron
KR20240171516A (ko) 2023-05-30 2024-12-09 주식회사 디앤아이바이오 미라베그론 서방정
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07119189B2 (ja) 1989-09-28 1995-12-20 北陸製薬株式会社 光学活性なベンジルアルコール誘導体及びその用途
GB9107827D0 (en) 1991-04-12 1991-05-29 Fujisawa Pharmaceutical Co New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
IL104567A (en) 1992-02-03 1997-03-18 Fujisawa Pharmaceutical Co Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
JPH06293664A (ja) 1993-04-05 1994-10-21 Fujisawa Pharmaceut Co Ltd β３−アドレナリン作動薬の新規医薬用途
JPH08509491A (ja) 1993-04-26 1996-10-08 藤沢薬品工業株式会社 胃腸疾患の治療に有用なエタノールアミン誘導体
JPH07228543A (ja) 1994-02-16 1995-08-29 Fujisawa Pharmaceut Co Ltd β３−アドレナリン作動薬の新規医薬用途
AU715216B2 (en) 1995-10-26 2000-01-20 Mitsubishi-Tokyo Pharmaceuticals, Inc. Phenylethanolamine compounds useful as beta3 agonist, process for producing the same, and intermediates in the production of the same
EP0932401A1 (en) * 1996-07-01 1999-08-04 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
KR20000068208A (ko) 1996-08-19 2000-11-25 간자와 무츠와 빈뇨 및 요실금의 예방·치료제
CA2302496C (en) * 1997-08-28 2009-12-08 Afferon Corporation Urinary incontinence therapy
DK1028111T3 (da) * 1997-10-17 2004-09-20 Yamanouchi Pharma Co Ltd Amidderivater eller salte heraf
NZ505103A (en) * 1997-12-18 2003-03-28 Kissei Pharmaceutical Phenylaminoalkylcarboxylic acid derivatives useful as beta 3 adrenoceptor stimulants
EP1072583B1 (en) 1998-04-14 2004-09-01 Kissei Pharmaceutical Co., Ltd. 2-methylpropionic acid derivatives and medicinal compositions containing the same
MY126489A (en) 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
WO2000047771A2 (en) 1999-02-12 2000-08-17 Genset Biallelic markers derived from genomic regions carrying genes involved in arachidonic acid metabolism
GB2356197A (en) 1999-10-12 2001-05-16 Merck & Co Inc Amide derivatives as beta 3 agonists
JP2001114736A (ja) 1999-10-19 2001-04-24 Kissei Pharmaceut Co Ltd ２−アミノプロパノール誘導体
CA2398199A1 (en) 2000-01-28 2001-08-02 Asahi Kasei Kabushiki Kaisha Novel therapeutic agents that use a .beta.3 agonist
AUPQ585000A0 (en) 2000-02-28 2000-03-16 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
AR035605A1 (es) 2000-12-11 2004-06-16 Bayer Corp Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores
US7342117B2 (en) 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
EP1879578A4 (en) * 2005-03-21 2009-05-13 Dov Pharmaceutical Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE

Also Published As

Publication number Publication date
NZ539577A (en) 2007-06-29
NO20052691L (no) 2005-07-15
CA2503570C (en) 2011-04-19
ATE500827T1 (de) 2011-03-15
EP1559427A4 (en) 2007-05-30
US8835474B2 (en) 2014-09-16
BR0316080A (pt) 2005-09-27
PL376771A1 (pl) 2006-01-09
CY2013023I2 (el) 2015-10-07
PL211687B1 (pl) 2012-06-29
MXPA05004925A (es) 2005-08-18
US7750029B2 (en) 2010-07-06
US20060115540A1 (en) 2006-06-01
IL168121A (en) 2011-12-29
CN100406011C (zh) 2008-07-30
ES2360353T3 (es) 2011-06-03
US20090093529A1 (en) 2009-04-09
RU2005117367A (ru) 2006-01-20
BE2013C040I2 (enExample) 2023-03-07
RU2321401C2 (ru) 2008-04-10
KR100967070B1 (ko) 2010-07-01
AU2003284700A1 (en) 2004-06-07
USRE44872E1 (en) 2014-04-29
CY2013023I1 (el) 2015-10-07
FR13C0032I1 (enExample) 2013-08-09
LU92218I9 (enExample) 2019-01-17
NO334948B1 (no) 2014-08-04
NO20052691D0 (no) 2005-06-06
AU2003284700B2 (en) 2009-05-28
CA2503570A1 (en) 2004-05-21
KR20050072809A (ko) 2005-07-12
FR13C0032I2 (fr) 2014-03-07
EP1559427A1 (en) 2005-08-03
NO2015001I2 (no) 2015-01-26
CN1711085A (zh) 2005-12-21
JPWO2004041276A1 (ja) 2006-03-02
SI1559427T1 (sl) 2011-06-30
WO2004041276A1 (ja) 2004-05-21
JP3815496B2 (ja) 2006-08-30
PT1559427E (pt) 2011-05-27
EP1559427B1 (en) 2011-03-09
CY1111399T1 (el) 2015-08-05
ZA200503510B (en) 2006-12-27
US20110230530A1 (en) 2011-09-22
NL300599I2 (enExample) 2017-01-03
HUS1300027I1 (hu) 2016-08-29
NO2015001I1 (no) 2015-01-19
LU92218I2 (fr) 2014-01-07
DK1559427T3 (da) 2011-04-26

Similar Documents

Publication Publication Date Title
DE60336334D1 (de) Mittel zur behandlung von blasenhyperaktivität mit einem essigsäureanilid-derivat als wirkstoff
EA200100721A1 (ru) Производное габапентина для предупреждения и лечения висцеральной боли
EA200000874A1 (ru) Индол - 3- пропионовые кислоты, их соли и эфиры, используемые в качестве лекарств
DE69011703D1 (de) Therapeutisches Arzneimittel gegen Thrombose und Verfahren zur Herstellung.
ATE402175T1 (de) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1, - naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
DE69916632D1 (de) Verwendung von zimtsäurederivaten zur herstellung eines medikamentes zur vorbeugung oder behandlung von erkrankungen die durch einen hohen blutfettspiegel bedingt sind
ATE171372T1 (de) Verwendung eines antagonisten der substanz p zur behandlung von hautrötungen neurogen ursprungs
ATE173620T1 (de) Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs
ATE289196T1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
Romer Pharmacological evaluation of mild analgesics.
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE60007548D1 (de) Omega kettenmodifizierte hydroxyeicosatetraensäure derivate verwendbar in der behandlung der "trockenes auge" krankheit
DE602004023564D1 (de) Verwendung von Citrullin zur Herstellung eines Arzneimittels zur Behandlung von ans Altern oder an eine Bestrahlung gebundener intestinaler Insuffizienz
DE602004003173D1 (de) Verwendung von konjugierter Linolsäure zur Behandlung der Erkältung
EP1691779A4 (en) STATUS TREATMENT IN MAMMALS BY ADMINISTRATION OF COMPOUNDS, AND METHODS OF USING THE SAME
ATE239492T1 (de) Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen
ATE401878T1 (de) Verwendung von phenoxyessigsäurederivaten zur behandlung der hyperaktiven blase
RU96107303A (ru) Способ оценки адекватности лечения
DE602004007546D1 (de) Verwendung von pentadiensäure-derivaten zur behandlung von hyperurikämie
Cox Theory and Management of the Downer Cow
RU2004123072A (ru) Способ лечения больных остеоартрозом
RU2000125470A (ru) Способ диагностики венозной патологии нижних конечностей
RU2004116493A (ru) Способ диагностики нестабильности плечевого сустава
RU2004131111A (ru) Способ лечения регенерирующих ран у собак
EP1432736A4 (en) METHODS FOR DIAGNOSING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH C $ G PROTEIN KINASE (L)